Who is sponsoring NCT00653913?

NCT00653913 is sponsored by Organon and Co.

What condition does NCT00653913 study?

NCT00653913 studies Hypercholesterolemia.

What drugs are being tested in NCT00653913?

Interventions: SCH 58235, pitavastatin.

What is the status of NCT00653913?

NCT00653913 is currently COMPLETED.

Last reviewed 2022-02-07 · How we verify

Evaluation of Potential for Pharmacokinetic Drug Interaction Between SCH 58235 and Pitavastatin

NCT00653913 Phase 1 COMPLETED

This study was designed to evaluate the pharmacokinetic interaction and safety of coadministration of SCH 58235 (ezetimibe) and pitavastatin in healthy Japanese adult male subjects or adult male subjects having no obvious disease other than high cholesterol levels.

Details

Lead sponsor	Organon and Co
Phase	Phase 1
Status	COMPLETED
Enrolment	18
Start date	2004-03
Completion	2004-09

Conditions

Hypercholesterolemia

Interventions

SCH 58235
pitavastatin

Primary outcomes

Compare plasma concentrations of SCH 58235 (ezetimibe) and pitavastatin after administration of each drug alone and in combination, using Cmax and AUC(0-24h). — Day 7 of each period